Fig. 3
From: Transitional and CD21− PD-1+ B cells are associated with remission in early rheumatoid arthritis
Transitional and CD21−PD-1+B cells in eRA at diagnosis and association with 24-week CDAI, by treatment. (A) Scatter plot and Spearman’s Rank correlation analyses of transitional B-cell (CD24++CD38++; in total B cells) frequency at diagnosis against 24-week follow-up CDAI in the following treatment arm; MTX and Prednisolone (N = 12), MTX and anti-TNF (N = 22), MTX and CTLA4-Ig (N = 16), MTX and anti-IL-6R (N = 19). (B) Scatter plot and Spearman’s Rank correlation analyses of CD21− PD-1+ B-cell (of parent population CD21− B cells) frequency at diagnosis against 24-week follow-up CDAI in the following treatment arm; MTX and Prednisolone (N = 12), MTX and anti-TNF (N = 22), MTX and CTLA4-Ig (N = 17), MTX and anti-IL-6R (N = 19). (C) Frequency of transitional B cells in eRA patients at diagnosis, subdivided by 24-week follow-up CDAI components in MTX and Prednisolone treatment arm, Mann-Whitney U-test and Pearson test. (D) Frequency of transitional B cells in eRA patients at diagnosis, subdivided by 24-week follow-up CDAI components in MTX and anti-IL-6R treatment arm, Mann-Whitney U-test and Spearman’s Rank correlation analyses. Horizontal lines indicate the median value. *p < 0.05; ns: non-significant. eRA: early Rheumatoid Arthritis; MTX: Methotrexate; anti-TNF: (certolizumab-pegol); CTLA4-Ig (abatacept); anti-IL-6R: (tocilizumab); CDAI: Clinical Disease Activity Index